Search Results
Your search for Nadine M. Tung, MD matches 12 pages
Showing 1 - 12New Fellows of the American Society of Clinical Oncology
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients will be recognized during the Opening Session of the Annual Meeting on Saturday, June 3. The following members are being recognized in 2023: Kerin Adelson, MD,...
New Fellows of the American Society of Clinical Oncology (FASCO)
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients will be recognized during the Opening Session of the Annual Meeting on Saturday, June 3. The following members are being recognized in 2023: Kerin Adelson, MD,...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of the OlympiA trial, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival ...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of the OlympiA trial, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival ...
Expert Point of View: Nadine M. Tung, MD
Formal discussant of OlympiA, Nadine M. Tung, MD, Director of Breast Medical Oncology and the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center and Harvard Medical School, was enthusiastic about the ability of olaparib to improve invasive disease–free survival and...
Breast Cancer Susceptibility Genes: Putting the Pieces Together
With the widespread use of multigene panels for germline genetic testing, understanding the cancer risks associated with pathogenic or likely pathogenic variants (ie, mutations) has become increasingly necessary. To identify which genes are breast cancer susceptibility genes, population studies...
Olaparib for Patients With Metastatic Breast Cancer and Mutations in Homologous Recombination–Related Genes
In a phase II Translational Breast Cancer Research Consortium (TBCRC) study (TBCRC 048; Olaparib Expanded) reported in the Journal of Clinical Oncology, Nadine M. Tung, MD, and colleagues found that olaparib produced high response rates in patients with metastatic breast cancer and germline PALB2...
Joint Guideline Sheds Light on Management of Hereditary Breast Cancer
As germline genetic testing becomes more widespread among patients with breast cancer, recommendations for the appropriate management of patients with hereditary breast cancer are needed. Until now, no ASCO guideline has addressed the management of hereditary breast cancer, even for carriers of...
Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide for Patients With HER2-Negative Breast Cancer and a BRCA Mutation
In a phase II trial (INFORM; Translational Breast Cancer Research Consortium [TBCRC] 031) reported in the Journal of Clinical Oncology, Nadine Tung, MD, and colleagues found that neoadjuvant cisplatin did not improve pathologic complete response rate or residual cancer burden vs...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Neoadjuvant Cisplatin for BRCA-Mutation Carriers: Pruning the Dead Branches
At the 2019 San Antonio Breast Cancer Symposium, Nadine Tung, MD, of Beth Israel Deaconess Medical Center, presented a multisite study called INFORM, run by the Translational Breast Cancer Research Consortium.1 It compared single-agent cisplatin with a “classic” combination of doxorubicin and...
Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide
Nadine M. Tung, MD, of Beth Israel Deaconess Medical Center, discusses cisplatin vs doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment in BRCA-mutation carriers with HER2-negative breast cancer. Although cisplatin as a single agent shows activity in this setting, the pathologic complete...
